Last Update Time:
13-Mar-2025 16:00:00
ISIN:
INE594H01019
Sector:
Healthcare
Symbol:
THYROCARE
Thyrocare Technologies Limited
₹700.00
₹24.55
(3.63%)
▲
Prev. Close
₹675.45
Open
₹680.90
Close
₹700.25
Range
₹665.00 - ₹735.00
High
₹703.75
Low
₹671.85
Ind. Close
₹0.00
VWAP
₹693.71
The current stock price of Thyrocare Technologies Limited is ₹700.00, with a target price range between ₹665.00 and ₹735.00. The stock has experienced a price change of ₹24.55 (3.63%), reflecting recent market volatility.
Today's opening price was ₹680.90, while the previous close stood at ₹675.45.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Thyrocare Technologies Limited Price Chart
Thyrocare Technologies Limited Pre Open Market Overview: 13-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 680.9
- Previous Close Price: 675.45
- Change: 5.45%
- Total Traded Volume: 5
- Total Buy Quantity: 580
- Total Sell Quantity: 1,235
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 666.60 | 5.00 | 0.00 |
| 667.00 | 10.00 | 0.00 |
| 669.70 | 20.00 | 0.00 |
| 670.00 | 1.00 | 0.00 |
| 676.00 | 10.00 | 0.00 |
| 680.90 | 0.00 | 8.00 |
| 680.95 | 0.00 | 5.00 |
| 682.00 | 0.00 | 91.00 |
| 682.10 | 0.00 | 15.00 |
| 682.25 | 0.00 | 14.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 580
Total Sell Quantity: 1235
Shareholding Patterns of Thyrocare Technologies Limited
Key Trade Statistics of Thyrocare Technologies Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.42 |
| Traded Value (₹ Cr.) | 2.92 |
| Total Market Cap (₹ Cr.) | 3,709.54 |
| Free Float Market Cap (₹ Cr.) | 1,067.67 |
| Impact cost | 0.14 |
| Quantity Traded | 42,042.00 |
| Deliverable Quantity | 25,719.00 |
| % of Quantity to Traded | 61.17 |
| Security VaR | 15.38 |
| Index VaR | N/A |
| VaR Margin | 15.38 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | 56.12 |
| Applicable Margin Rate | 75 |
| Face Value | 10 |
Key Price Statistics of Thyrocare Technologies Limited
The 52-week high for Thyrocare Technologies Limited was ₹1,055.00, recorded on 06-Jan-2025. On the other hand, the 52-week low stands at ₹554.10, with the lowest value recorded on 27-Mar-2024.
The upper band for trading is ₹810.50, and the lower band is ₹540.40. The price band is 20%.
The stock's daily volatility stands at 2.38, while the annualized volatility is 45.47. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (06-Jan-2025) | 1,055.00 |
| 52 Week Low (27-Mar-2024) | 554.10 |
| Upper Band | 810.50 |
| Lower Band | 540.40 |
| Price Band (%) | 20 |
| Daily Volatility | 2.38 |
| Annualised Volatility | 45.47 |
| Tick Size | 0.05 |
Key Securities Statistics of Thyrocare Technologies Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 09-May-2016 |
| Adjusted P/E | 34.31 |
| Symbol P/E | 34.36 |
| Index | NA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Basic Industry | Healthcare Service Provider |
Security Status of Thyrocare Technologies Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Thyrocare Technologies Limited
| Subject | Date |
|---|---|
| Reply to Clarification- Financial results | 13-Mar-2025 |
| Acquisition-XBRL | 04-Mar-2025 |
| General Updates | 03-Mar-2025 |
| Clarification - Financial Results | 19-Feb-2025 |
| Integrated Filing- Financial | 03-Feb-2025 |
| Updates | 03-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 27-Jan-2025 |
| Copy of Newspaper Publication | 25-Jan-2025 |
Corporate Actions of Thyrocare Technologies Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Dividend - Rs 18 Per Share | 16-Aug-2024 |
| 10 | Interim Dividend - Rs 18 Per Share | 20-Apr-2023 |
| 10 | Annual General Meeting | 25-Jul-2022 |
| 10 | Interim Dividend - Rs 15 Per Share | 11-May-2022 |
| 10 | Annual General Meeting/Dividend - Rs 15 Per Share | 17-Jun-2021 |
| 10 | Interim Dividend - Rs 10 Per Share | 12-Nov-2020 |
| 10 | Interim Dividend - Rs 5 Per Share | 21-Nov-2019 |
| 10 | Dividend - Rs 20 Per Share | 14-Aug-2019 |
| 10 | Annual General Meeting/Dividend- Rs 5 Per Share | 02-Aug-2018 |
| 10 | Interim Dividend Rs 5/- Per Share | 15-Feb-2018 |
| 10 | Annual General Meeting/Dividend - Rs 5/- Per Share | 03-Aug-2017 |
| 10 | Interim Dividend Rs 5/- Per Share (Purpose Revised) | 08-Feb-2017 |
| 10 | Annual General Meeting/Dividend - Rs 2.50 Per Share | 01-Sep-2016 |
Board Meetings of Thyrocare Technologies Limited
Financial Results of Thyrocare Technologies Limited
Company Directory of Thyrocare Technologies Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.thyrocare.com | Registered Office | D/37-1, TTC Industrial Area MIDC Turbhe Navi Mumbai 400 703 |
NAVI MUMBAI |
Insider Trading of Thyrocare Technologies Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Priyanka Jagnani Jain | 152200 | Buy |
| 7(2) | Priyanka Jagnani Jain | 190224 | Buy |
| 7(2) | Priyanka Jagnani Jain | 425058 | Buy |
| 7(2) | Rahul Guha | 1072337 | Buy |
| 7(2) | Rahul Guha | 19425 | Buy |
| 7(2) | DOCON TECHNOLOGIES PRIVATE LIMITED | 0 | Pledge |
| 7(2) | Alok Kumar Jagnani | 109550 | Sell |
| 7(2) | Alok Kumar Jagnani | 100275 | Buy |
| 7(2) | Alok Kumar Jagnani | 296961 | Sell |
| 7(2) | Mr. Rahul Guha | 4309725 | Buy |
| 7(2) | Alok Kumar Jagnani | 287686 | Buy |
| 7(2) | DOCON TECHNOLOGIES PRIVATE LIMITED | 0 | Pledge |
| 7(2) | Mr. Rahul Guha | 10199192 | Buy |
| 7(2) | DOCON TECHNOLOGIES PRIVATE LIMITED | 0 | Pledge |
| 7(2) | DOCON TECHNOLOGIES PRIVATE LIMITED | 0 | Pledge |
| 7(2) | Mr. Rahul Guha | 15775094 | Buy |
| 7(2) | DOCON TECHNOLOGIES PRIVATE LIMITED | 23467276534 | Pledge |
| 7(2) | DOCON TECHNOLOGIES PRIVATE LIMITED | 23467276534 | Pledge Revoke |
| 7(2) | Dr. A. Velumani | 19262977500 | Sell |
| 7(2) | Miss. Amruta Velumani | 978265600 | Sell |
Annual Reports of Thyrocare Technologies Limited
Investor Complaints of Thyrocare Technologies Limited
Event Calendar of Thyrocare Technologies Limited
| Purpose | Details |
|---|---|
| Results/Dividend | inter alia, the following subjects:1) Audited Stand-alone financial results of the Company for the quarter and financial year ended March 31, 2016 and Audited , consolidated financial results of the Company and its subsidiary for the quarter and financial year ended March 31, 2016.2) Recommending final dividend , if any, for the financial year ended March 31,2016.3)Granting of Employee Stock Options for the financial year ended March 31, 2016. |
| Results | To, inter alia, consider and approve unaudited Stand-alone and Consolidated Financial Results for the Quarter ended June 30, 2016 |
| Results | to inter alia, consider and approve unaudited Stand-alone and Consolidated financial results of the Company for the quarter / half year ended September 30, 2016. Also pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading window of the Company will remain closed for trading in Company s equity shares for Directors / Designated Employees of the Company from October 17, 2016 to October 28, 2016 (both days inclusive). The trading window will reopen on Monday, October 31, 2016. |
| Results/Dividend | to consider, inter alia, the Unaudited Stand-alone as well as Consolidated financial results of the Company for the quarter / nine months ended December 31, 2016. The Board will also consider payment of interim dividend, if any, after taking into consideration the capital expenditure and other cash requirements for the remaining period of the current financial year and the next financial year. |
| Results | Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Tuesday, the 9th May 2017, at the Corporate Office of the Company, inter alia, to consider and approve Stand-alone and Consolidated Audited Financial Results of the Company for the quarter / financial year ended March 31, 2017 and to consider granting of Employee Stock Options for the financial year ended March 31, 2017. Please also note that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading window of the Company will remain closed for trading in Company s equity shares for Directors / Designated Employees / Connected Persons from May 03, 2017 to May 12, 2017 (both days inclusive). |
| Results | Inter alia, to consider and approve unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter ended June 30, 2017. |
| Results/Dividend | To, inter alia: (1) Consider and approve unaudited Standalone as well as Consolidated Financial Results of the Company for the quarter /half year ended September 30, 2017.(2) Consider declaration of Interim Dividend for the Financial Year 2017-18. |
| Results/Dividend | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on February 03, 2018 inter alia, to consider and approve Unaudited Stand-alone as well as Consolidated Financial Results of the Company for the quarter / nine months ended December 31, 2017. The Company has now informed the Exchange that the Board may consideration of declaring an interim dividend .(Purpose Revised) |
| Results | inter alia, to consider and approve Unaudited Stand-alone as well as Consolidated Financial Results of the Company for the quarter / nine months ended December 31, 2017. |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results (Stand-alone and Consolidated) for the period ended March 31, 2018, dividend and other business matters |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2018 and interim dividend if any |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2019, dividend and other business matters |
| Other business matters | To consider other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2019 and other business matters |
| Other business matters | To consider other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended September 30, 2019, dividend and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2019, dividend and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2020, dividend and other business matters |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2020 and dividend |
| Other business matters | To consider other business matters |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2020 and dividend |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2020, dividend and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2021, dividend and other business matters |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on 01-Aug-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Dividend | To consider dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and recommendation of final dividend, if any |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the quarter and half year ended September 30, 2024 |
| Financial Results | To consider and approve the Unaudited Standalone and Consolidated financial results for the Quarter ended December 31, 2024. |
Share Transfers of Thyrocare Technologies Limited
Voting Results of Thyrocare Technologies Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 09-JAN-2025 | Postal Ballot | Extension of the Thyrocare Employees Stock Option Scheme to eligible employee(s) of the Holding and/or Subsidiary Companies of the Company. |
| 23-AUG-2024 | AGM | 1 - (a)tTo adopt the audited standalone financial statements of the Company for the financial year ended March 31, 2024, together with the Board￢ﾀﾙs Report and the Auditors￢ﾀﾙ Report thereon; andnn(b)t To adopt the audited consolidated financial statements of the Company for the financial year ended March 31, 2024, together with the Auditors￢ﾀﾙ Report thereon. |
| 23-AUG-2024 | AGM | To authorise the Board to make investments, give loans, guarantees and security in excess of limits specified under Section 186 of the Companies Act, 2013. |
| 23-AUG-2024 | AGM | To approve entering into material related party transactions with Docon Technologies Private Limited. |
| 23-AUG-2024 | AGM | To ratify / approve the remuneration fixed for the cost auditor for the financial year 2024-25. |
| 23-AUG-2024 | AGM | To approve appointment of Mr. Anandh Sundar (DIN: 10409065) as an Independent Director. |
| 23-AUG-2024 | AGM | To approve appointment of Mr. Nishant Amilal Shah (DIN: 09025935) as an Independent Director. |
| 23-AUG-2024 | AGM | To appoint a director in the place of Mr. Hardik Dedhia (DIN: 06660799), who retires by rotation, and being eligible, offers himself re-appointment. |
| 23-AUG-2024 | AGM | To declare dividend of Rs.18/- per equity share of face value of Rs.10/- each for the financial year 2023-24. |
| 10-AUG-2023 | AGM | To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended March 31, 2023, together with the Board￢ﾀﾙs Report and the Auditors￢ﾀﾙ Report thereon; and the audited consolidated financial statements of the Company for the financial year ended March 31, 2023, together with the Auditors￢ﾀﾙ Report thereon |
| 10-AUG-2023 | AGM | Granting of Employees Stock Option for financial year 2023-24 and subsequent years in accordance with the revised scheme until the remaining 218,662 stock options are fully utilised and equivalent no. of shares and issued and allotted |
| 10-AUG-2023 | AGM | Amendment in the Employee Stock Option Scheme |
| 10-AUG-2023 | AGM | Approval for entering into material related party transactions with Docon Technologies Private Limited |
| 10-AUG-2023 | AGM | Ratification of remuneration to the cost auditor for the financial year 2023-24 |
| 10-AUG-2023 | AGM | Appointment of Dr. Harshil Jiten Vora (DIN:10232581) as a Non-Executive Independent Director |
| 10-AUG-2023 | AGM | Appointment of Dr. Prapti Ishwar Gilada (DIN: 07125024) as a Non-Executive Independent Director |
| 10-AUG-2023 | AGM | Reappointment of Dr. Indumati Gopinathan (DIN: 06779331) as a Non-Executive Independent Director |
| 10-AUG-2023 | AGM | Appointment of Mr. Rahul Guha (DIN: 09588432), Managing Director and Chief Executive Officer as Chairman of the Company |
| 10-AUG-2023 | AGM | To appoint a Director in the place of Mr. Dharmil Sheth (DIN: 06999772), who retires by rotation, and being eligible, offers himself for re-appointment |
| 10-AUG-2023 | AGM | To confirm the payment of Interim Dividend of Rs.18/- per equity share already paid for the Financial Year 2022-23 and treat it as the Final Dividend for the financial year 2022-23 |
FAQs on Thyrocare Technologies Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.